We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

39 hedge funds and large institutions have $6.57M invested in ImmunityBio in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $6.47M → $6.57M (+$98.7K)

0.94% less ownership

Funds ownership: 6.42% → 5.48% (-0.94%)

17% less funds holding

Funds holding: 47 → 39 (-8)

31% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 13

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

75% less call options, than puts

Call options by funds: $13K | Put options by funds: $53K

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
13
Closed
14
Calls
$13K
Puts
$53K
Net Calls
-$40K
Net Calls Change
+$12K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$124K
2
Renaissance Technologies
Renaissance Technologies
New York
+$103K
3
TRCT
Tower Research Capital (TRC)
New York
+$57.9K
4
Charles Schwab
Charles Schwab
California
+$57.7K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$39.7K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$518K
2
Northern Trust
Northern Trust
Illinois
-$269K
3
PP
Paloma Partners
Connecticut
-$127K
4
Jane Street
Jane Street
New York
-$92K
5
WCM
Wildcat Capital Management
New York
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFS
51
Sowell Financial Services
Arkansas
– +$12 +10 New
1 2
3

IBRX Hedge Fund Activity: Q3 2019 in Review

39 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2019, worth a combined $6.57M — up 1.5% from $6.47M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of IBRX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $124K. The largest seller was Millennium Management, cutting an estimated $518K.

  • 39 institutional investors held ImmunityBio (IBRX) as of Q3 2019, down from 47 in Q2 2019.
  • Funds reported $6.57M of ImmunityBio stock for Q3 2019, up 1.5% quarter-over-quarter.
  • 6 funds opened new ImmunityBio positions in Q3 2019 and 14 closed out, a net change of -8 holders.
  • The largest ImmunityBio buyer in Q3 2019 was Vanguard Group, an estimated $124K added.
  • The largest ImmunityBio seller in Q3 2019 was Millennium Management, an estimated $518K sold.

Based on aggregated 13F filings for Q3 2019.